Back

Real-world data on the use of mavacamten in obstructive hypertrophic cardiomyopathy: one-year data from the multicentre MARVEL.HU study involving 133 patients

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibitors: real-world data Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Robert Sepp

University of Szeged, Szeged (Hungary)

4 More presentations in this session

Presentation thumbnail
Predictors of functional status and quality-of-life improvement with mavacamten in obstructive hypertrophic cardiomyopathy: one-year results from a real-world nationwide cohort
Doctor G. Bonacchi (Florence, IT)
Abstract Slides Video
Presentation thumbnail
From evidence to practice: Mavacamten in obstructive Hypertrophic Cardiomyopathy - data from the multicenter TORCH-Plus-DZHK21 registry
Doctor J. Koelemen (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Real-world experience and structural remodeling with cardiac myosin inhibitors in hypertrophic obstructive cardiomyopathy: Insights from a Heart Failure Network Registry
Doctor D. Jurczyk (Luebeck, DE)
Abstract Slides Video
Presentation thumbnail
Correlation of electrocardiographic reverse remodelling with treatment response to mavacamten in hypertrophic obstructive cardiomyopathy
Mr M. Menhem (Erlangen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac myosin inhibitors: real-world data

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Consistent real world effectiveness of mavacamten across global regions in symptomatic obstructive hypertrophic cardiomyopathy: results from COLLIGO HCM
30 August 2026
thumbnail
Congress Presentation
Atrial fibrillation during mavacamten treatment in obstructive hypertrophic cardiomyopathy in the real-world: data from the multicenter MARVEL.HU registry on 133 patients
30 August 2026
thumbnail
Congress Presentation
Hypertrophic obstructive cardiomyopathy and magnetic resonance imaging: exploring the impact of mavacamten
9 May 2026
thumbnail
Congress Presentation
Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources